Navigation Links
Malignant tumor or benign cyst?
Date:3/10/2008

The results of a study presented today at the Society of Gynecologic Oncologys 39th Annual Meeting on Womens Cancer offer a promising development on the path toward better management of ovarian cancer. Researchers say testing women suspected of having ovarian cancer for a combination of proteins, or biomarkers in the blood called HE4 and CA 125, could be the key to predicting a womans risk for the disease dubbed the silent killer. Currently there is no adequate diagnostic test for ovarian cancer.

Roughly 20 percent of women will be diagnosed with an ovarian cyst or tumor at some point in their life, and only a small percentage of these women will be diagnosed with ovarian cancer, said Lead Researcher Richard Moore, M.D., assistant professor at The Warren Alpert Medical School of Brown University and a gynecologic oncologist in the Program in Womens Oncology at Women & Infants Hospital of Rhode Island. The problem is that current methods for distinguishing benign ovarian tumors from malignant ones are limited and as a result, women must undergo surgery without an accurate assessment as to their risk for having ovarian cancer prior to their surgery.

Dr. Moore notes that fewer than half of all ovarian cancer patients have their initial surgery performed by a gynecologic oncologist or surgeon with specialized training in the management of ovarian cancer. Our research is aimed at identifying patients at high risk for harboring an ovarian cancer so that they receive the right care from the right physician.

Currently, CA 125 is the only blood test that can be used to help predict a womans risk for ovarian cancer and to help with the clinical management of the disease. However, CA 125 alone lacks the sensitivity required for the detection of ovarian cancer prompting researchers to look at the ability of combinations of biomarkers to predict the presence of ovarian cancer. Earlier this year, Dr. Moore published results of a pilot study in the journal of Gynecologic Oncology evaluating nine potential biomarkers and the ability of multiple marker combinations to predict the risk for ovarian cancer in women. His findings showed the combination of HE4 and CA 125 provided the highest level sensitivity and specificity out of all marker combinations for predicting the presence of ovarian cancer.

In a prospective, double-blinded, multicenter clinical trial, Dr. Moore and his team studied 496 women presenting with pelvic mass or ovarian cysts to determine if tests targeting multiple markers utilizing HE4 and CA 125 and a predictive algorithm could accurately assess the risk for epithelial ovarian cancer prior to surgery. Researchers measured levels of the biomarkers within the womens blood and then compared the results with biopsies of their tumors. The combination of biomarkers performed well in both pre- and post-menopausal women, accurately stratifying 95 percent of patients with epithelial cancer as high risk and 75 percent of benign cases as low risk.

Studies suggest women with ovarian cancer have better outcomes and increased survival when treated by surgeons trained in the management of ovarian cancer and at institutions specializing in the care of women with this disease, adds Dr. Moore. By using the combination of HE4 and CA 125 as a model to assess a womens risk for ovarian cancer, physicians can better triage patients for care and refer them to the appropriate specialist whether at a community hospital or large academic institution.

Together, HE4 and CA 125 offer a powerful combination that could dramatically change the way ovarian cancer is managed at all stages of care, said Dr. Olle Nilsson, vice president and chief scientific officer of Fujirebio Diagnostics, the developers of the CA 125 test. As research continues to progress, it is our hope that a test for HE4 and CA 125 could eventually lead to a plausible screening tool.

Fujirebio Diagnostics has developed a manual test for HE4 and will be developing automated formats of the test for Fujirebio instruments. The HE4 test is CE marked in Europe. The company has applied to the U.S. Food and Drug Administration (FDA) and hopes to see availability of the test in late 2008.


'/>"/>

Contact: Stephanie Euler
stephanie@sternassociates.com
908-276-4344 x213
Fujirebio Diagnostics
Source:Eurekalert

Related medicine news :

1. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
2. iNOS expression may links chronic biliary inflammation to malignant transformation
3. Protein in embryonic stem cells control malignant tumor cells
4. Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells
5. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
6. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
7. Study details regulation of vital tumor suppressor gene p53
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Customized virus kills brain tumor stem cells that drive lethal cancer
10. Study suggests brain tumors need treatment with multiple targeted drugs
11. Bright tumors, dim prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology: